Insulet (NASDAQ:PODD) Trading 4.8% Higher

Insulet Co. (NASDAQ:PODD - Get Free Report)'s share price traded up 4.8% on Tuesday . The stock traded as high as $179.48 and last traded at $178.13. 241,594 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 882,331 shares. The stock had previously closed at $170.04.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Stifel Nicolaus upped their target price on shares of Insulet from $163.00 to $208.00 and gave the company a "hold" rating in a report on Monday, February 5th. Robert W. Baird raised shares of Insulet from a "neutral" rating to an "outperform" rating and upped their target price for the company from $180.00 to $238.00 in a report on Thursday, December 21st. Piper Sandler reduced their target price on shares of Insulet from $250.00 to $230.00 and set an "overweight" rating for the company in a report on Friday, February 23rd. JPMorgan Chase & Co. upped their target price on shares of Insulet from $190.00 to $225.00 and gave the company an "overweight" rating in a report on Friday, February 23rd. Finally, Barclays reduced their target price on shares of Insulet from $214.00 to $213.00 and set an "equal weight" rating for the company in a report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $250.33.

Insulet Stock Up 4.7 %

The company has a debt-to-equity ratio of 1.86, a current ratio of 3.51 and a quick ratio of 2.62. The firm's 50-day simple moving average is $177.68 and its two-hundred day simple moving average is $178.43. The company has a market capitalization of $12.45 billion, a price-to-earnings ratio of 61.17, a price-to-earnings-growth ratio of 2.97 and a beta of 0.98.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.73. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The company had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. During the same period in the prior year, the business posted $0.55 earnings per share. The firm's revenue for the quarter was up 37.9% compared to the same quarter last year. Sell-side analysts predict that Insulet Co. will post 3.08 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total value of $1,891,338.28. Following the sale, the director now directly owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.80% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

Large investors have recently modified their holdings of the business. First Manhattan Co. acquired a new stake in shares of Insulet in the fourth quarter valued at approximately $35,000. Wolff Wiese Magana LLC lifted its stake in shares of Insulet by 2,680.0% during the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier's stock valued at $30,000 after buying an additional 134 shares during the period. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Insulet during the fourth quarter valued at approximately $34,000. Parkside Financial Bank & Trust lifted its stake in shares of Insulet by 251.0% during the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 123 shares during the period. Finally, Allworth Financial LP lifted its stake in shares of Insulet by 104.5% during the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 92 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.